Patients with a previous history of erosive esophagitis A or B ( LA classification ) that was healed at the time of enrollment or endoscopy-negative reflux disease ( ENRD ) , documented with an abnormal pH study , were randomized to receive maintenance therapy with esomeprazole 40 mg twice daily ( group A ) , once daily ( group B ) , or every other day ( group C ) .
